Nawaf Abdulaziz Alsaif

Dr. Nawaf Abdulaziz Alsaif

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
NANawaf Abdulaziz Alsaif
Nawaf Abdulaziz Alsaif
Mohammed Ahmed DahabMohammed Ahmed Dahab
Mohammed Ahmed Dahab
MAMohammed M Alanazi
Mohammed M Alanazi
AOAhmad J Obaidullah
Ahmad J Obaidullah
AAAbdulrahman A Al-Mehizia
Abdulrahman A Al-Mehizia
Hazem ElkadyHazem Elkady
Hazem Elkady

1 July 2020 in Bioorganic Chemistry
Verified
Journal Article
Closed access
TWTanveer A. Wani
Tanveer A. Wani
NANawaf Abdulaziz Alsaif
Nawaf Abdulaziz Alsaif
ABAhmed H. Bakheit
Ahmed H. Bakheit
SZSeema Zargar
Seema Zargar
AAAbdurrahman A. Al-Mehizia
Abdurrahman A. Al-Mehizia
Azmat Ali KhanAzmat Ali Khan
Azmat Ali Khan

1 January 2021 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
NANawaf Abdulaziz Alsaif
Nawaf Abdulaziz Alsaif
MTMohammed S. Taghour
Mohammed S. Taghour
ARA. F. M. Motiur Rahman
A. F. M. Motiur Rahman
AOAhmad Jomah Obaidullah
Ahmad Jomah Obaidullah
AAAbdulrahman Almehizia
Abdulrahman Almehizia
Hazem ElkadyHazem Elkady
Hazem Elkady
Herein, a new wave of bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives have been successfully designed and synthesised. The synthesised derivatives were biologically investigated for their cytotoxic activities against HepG2 and MCF-7. Also, the tested compounds were further examined in vitro for their VEGFR-2 inhibitory activity. The most promising derivative 23j was further investigated for its apoptotic behaviour in HepG2 cell lines using flow cytometric and western-plot analyses. Additional in-silico studies were performed to predict how the synthesised compounds can bind to VEGFR-2 and to determine the drug-likeness profiling of these derivatives. The results revealed that compounds 23a, 23i, 23j, 23l, and 23n displayed the highest antiproliferative activities against the two cell lines with IC50 values ranging from 6.4 to 19.4 µM. Furthermore, compounds 23a, 23d, 23h, 23i, 23j, 23l, 23 m, and 23n showed the highest VEGFR-2 inhibitory activities with IC50 values ranging from 3.7 to 11.8 nM, comparing to sorafenib (IC50 = 3.12 nM). Moreover, compound 23j arrested the HepG2 cell growth at the G2/M phase and induced apoptosis by 40.12% compared to the control cells (7.07%). As well, such compound showed a significant increase in the level of caspase-3 (1.36-fold), caspase-9 (2.80-fold), and BAX (1.65-fold), and exhibited a significant decrease in Bcl-2 level (2.63-fold).

18 April 2022 in Molecules
Verified
Journal Article
Open access
PDF file
SZSeema Zargar
Seema Zargar
TWTanveer A. Wani
Tanveer A. Wani
NANawaf Abdulaziz Alsaif
Nawaf Abdulaziz Alsaif
AKArwa Khayyat
Arwa Khayyat
Quetiapine (QTP) is a short-acting atypical antipsychotic drug that treats schizophrenia or manic episodes of bipolar disorder. Human serum albumin (HSA) is an essential transport protein that transports hormones and various other ligands to their intended site of action. The interactions of QTP with HSA and their binding mechanism in the HSA-QTP system was studied using spectroscopic and molecular docking techniques. The UV-Vis absorption study shows hyperchromicity in the spectra of HSA on the addition of QTP, suggesting the complex formation and interactions between QTP and HSA. The results of intrinsic fluorescence indicate that QTP quenched the fluorescence of HSA and confirmed the complex formation between HSA and QTP, and this quenching mechanism was a static one. Thermodynamic analysis of the HSA-QTP system confirms the involvement of hydrophobic forces, and this complex formation is spontaneous. The competitive displacement and molecular docking experiments demonstrated that QTP is preferentially bound to HSA subdomain IB. Furthermore, the CD experiment results showed conformational changes in the HSA-QTP system. Besides this, the addition of QTP does not affect the esterase-like activity of HSA. This study will help further understand the credible mechanism of transport and delivery of QTP via HSA and design new QTP-based derivatives with greater efficacy.

1 March 2021 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
TWTanveer A. Wani
Tanveer A. Wani
NANawaf Abdulaziz Alsaif
Nawaf Abdulaziz Alsaif
MAMohammed M. Alanazi
Mohammed M. Alanazi
ABAhmed H. Bakheit
Ahmed H. Bakheit
SZSeema Zargar
Seema Zargar
Mashooq Ahmad BhatMashooq Ahmad Bhat
Mashooq Ahmad Bhat

13 May 2021 in RSC Advances
Verified
Journal Article
Open access
PDF file
AOAhmad Jomah Obaidullah
Ahmad Jomah Obaidullah
ARA. F. M. Motiur Rahman
A. F. M. Motiur Rahman
NANawaf Abdulaziz Alsaif
Nawaf Abdulaziz Alsaif
HAHussam Albassam
Hussam Albassam
AAAbdulrahman Almehizia
Abdulrahman Almehizia
TETalha Bin Emran
Talha Bin Emran
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in a contagious respiratory tract infection that has become a global burden since the end of 2019. Notably, fewer patients infected with SARS-CoV-2 progress from acute disease onset to death compared with the progression rate associated with two other coronaviruses, SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). Several research organizations and pharmaceutical industries have attempted to develop successful vaccine candidates for the prevention of COVID-19. However, increasing evidence indicates that the SARS-CoV-2 genome undergoes frequent mutation; thus, an adequate analysis of the viral strain remains necessary to construct effective vaccines. The current study attempted to design a multi-epitope vaccine by utilizing an approach based on the SARS-CoV-2 structural proteins. We predicted the antigenic T- and B-lymphocyte responses to four structural proteins after screening all structural proteins according to specific characteristics. The predicted epitopes were combined using suitable adjuvants and linkers, and a secondary structure profile indicated that the vaccine shared similar properties with the native protein. Importantly, the molecular docking analysis and molecular dynamics simulations revealed that the constructed vaccine possessed a high affinity for toll-like receptor 4 (TLR4). In addition, multiple descriptors were obtained from the simulation trajectories, including the root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), solvent-accessible surface area (SASA), and radius of gyration (Rg), demonstrating the rigid nature and inflexibility of the vaccine and receptor molecules. In addition, codon optimization, based on Escherichia coli K12, was used to determine the GC content and the codon adaptation index (CAI) value, which further followed for the incorporation into the cloning vector pET28+(a). Collectively, these findings suggested that the constructed vaccine could be used to modulate the immune reaction against SARS-CoV-2.